Vanin1 (VNN1) in chronic diseases: Future directions for targeted therapy.

Hao Yu, Yuying Cui, Fangyue Guo, YuTong Zhu, Xiaonan Zhang, Dong Shang, Deshi Dong, Hong Xiang

Journal: European journal of pharmacology 2023;962():176220

PMID: 38042463

Free Full Text on Elsevier Science View on PubMed

Abstract

Vanin1 (VNN1) is an exogenous enzyme with pantetheinase activity that mainly exerts physiological functions through enzyme catalysis products, including pantothenic acid and cysteamine. In recent years, the crosstalk between VNN1 and metabolism and oxidative stress has attracted much attention. As a result of the ability of VNN1 to affect multiple metabolic pathways and oxidative stress to exacerbate or alleviate pathological processes, it has become a key component of disease progression. This review discusses the functions of VNN1 in glucolipid metabolism, cysteamine metabolism, and glutathione metabolism to provide perspectives on VNN1-targeted therapy for chronic diseases.

Address: Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, 116011, China; College of Pharmacy, Dalian Medical University, 116044, China.; Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China; Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116044, China.; Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China; Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116044, China; Department of General Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.; Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, 116011, China. Electronic address: [email protected].; Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China. Electronic address: [email protected].

DOI: 10.1016/j.ejphar.2023.176220